Equity Profile

GSK

GSK plc

Health CarePharmaceuticals$101.4B

Apr29Wed

Pre-Earnings Brief

UpcomingQ1-2026Pre-Market9:00 AM EDT

Company Snapshot

GSK plc is a global healthcare company focused on pharmaceuticals, vaccines, and consumer health products. With a market cap of $101 billion, GSK plays a significant role in addressing health challenges worldwide, particularly in the pharmaceutical sector.

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well GSK is managing costs and generating income.

$1.16

Revenue

Total revenue reflects the company's sales performance and growth in its product lines, which is crucial for investor confidence.

$7.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

GSK Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-32.34%

Avg Stock Reaction

-0.73%

Last Quarter Recap

In the last quarter, GSK faced challenges with earnings falling short of expectations, impacting investor sentiment. The company did not provide specific guidance for future performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect GSK to report earnings in line with consensus estimates, but there is uncertainty due to past performance. Investors are keen to see if GSK can turn around its recent trends.

Bull Case

If GSK exceeds EPS and revenue expectations, it could signal a recovery in its operations and boost investor confidence.

Bear Case

Conversely, if GSK misses estimates again, it may raise concerns about its growth strategy and market competitiveness.

Key Metrics to Watch

EPS

$1.16

Earnings per share is a key indicator of profitability and will show how well GSK is managing costs and generating income.

Revenue

$7.6B

Total revenue reflects the company's sales performance and growth in its product lines, which is crucial for investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will GSK achieve an EPS of at least $1.16?

This figure is critical as it will indicate whether GSK can stabilize its earnings after previous misses.

What is the outlook for revenue growth in key product areas?

Understanding revenue growth will help gauge GSK's market position and future potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating GSK's potential for a rebound in earnings, given recent product developments that could drive sales.

Supporting Evidence

Options are pricing a 9.71% move, indicating expectations for volatility that may not be justified by historical performance.

GSK's recent product launches have not been fully factored into earnings expectations, which could lead to upside surprises.

Key Risk

If GSK's new products show stronger than expected sales, it could significantly alter earnings forecasts.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal for GSK as it seeks to regain investor confidence after several disappointing results.

Bull Confirmed If

An EPS of $1.18 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $1.15 would confirm the bear case, raising concerns about GSK's profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±9.71%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±9.7% while GSK has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

25.1%

Calls (39K)P/C Ratio: 2.84Puts (15K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

19.80%

of float

Insider

0.06%

of float

Holders

1,142

institutions

Top Holders· as of Dec 2025

Dodge & Cox Inc.
68,517,969 sh · $3.7B
3.38%
-12.6%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GSK beats expectations, history suggests a modest positive reaction, potentially confirming a turnaround in performance.

In-Line / Cautious

If results are in line, the stock may react cautiously, reflecting ongoing uncertainty about future growth.

Miss

A miss could lead to a negative reaction, with history indicating a decline in stock price following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product sales and their impact on revenue.
2Management's commentary on cost management strategies.
3Insights into market share changes in key therapeutic areas.
4Future guidance on R&D investments and their expected returns.
5Responses to analyst questions regarding competitive pressures.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Apr27

OMABReported

Grupo Aeroportuario del Centro Norte, S.A.B. de C.V.

RecapView

Apr27

PIIReported

Company Snapshot

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well GSK is managing costs and generating income.

$1.16

Revenue

Total revenue reflects the company's sales performance and growth in its product lines, which is crucial for investor confidence.

$7.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

GSK Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-32.34%

Avg Stock Reaction

-0.73%

Last Quarter Recap

In the last quarter, GSK faced challenges with earnings falling short of expectations, impacting investor sentiment. The company did not provide specific guidance for future performance.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect GSK to report earnings in line with consensus estimates, but there is uncertainty due to past performance. Investors are keen to see if GSK can turn around its recent trends.

Bull Case

If GSK exceeds EPS and revenue expectations, it could signal a recovery in its operations and boost investor confidence.

Bear Case

Conversely, if GSK misses estimates again, it may raise concerns about its growth strategy and market competitiveness.

Key Metrics to Watch

EPS

$1.16

Earnings per share is a key indicator of profitability and will show how well GSK is managing costs and generating income.

Revenue

$7.6B

Total revenue reflects the company's sales performance and growth in its product lines, which is crucial for investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will GSK achieve an EPS of at least $1.16?

This figure is critical as it will indicate whether GSK can stabilize its earnings after previous misses.

What is the outlook for revenue growth in key product areas?

Understanding revenue growth will help gauge GSK's market position and future potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating GSK's potential for a rebound in earnings, given recent product developments that could drive sales.

Supporting Evidence

Options are pricing a 9.71% move, indicating expectations for volatility that may not be justified by historical performance.

GSK's recent product launches have not been fully factored into earnings expectations, which could lead to upside surprises.

Key Risk

If GSK's new products show stronger than expected sales, it could significantly alter earnings forecasts.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is pivotal for GSK as it seeks to regain investor confidence after several disappointing results.

Bull Confirmed If

An EPS of $1.18 or higher would confirm the bull case, indicating strong operational performance.

Bear Confirmed If

An EPS below $1.15 would confirm the bear case, raising concerns about GSK's profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±9.71%

Historical Avg

±2.0%

Pricing rich

The options market is pricing in a significant move, suggesting that investors are anticipating volatility around the earnings report.

Options are pricing ±9.7% while GSK has averaged ±2.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

25.1%

Calls (39K)P/C Ratio: 2.84Puts (15K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Mixed flows

Institutional

19.80%

of float

Insider

0.06%

of float

Holders

1,142

institutions

Top Holders· as of Dec 2025

Dodge & Cox Inc.
68,517,969 sh · $3.7B
3.38%
-12.6%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If GSK beats expectations, history suggests a modest positive reaction, potentially confirming a turnaround in performance.

In-Line / Cautious

If results are in line, the stock may react cautiously, reflecting ongoing uncertainty about future growth.

Miss

A miss could lead to a negative reaction, with history indicating a decline in stock price following earnings misses.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product sales and their impact on revenue.
2Management's commentary on cost management strategies.
3Insights into market share changes in key therapeutic areas.
4Future guidance on R&D investments and their expected returns.
5Responses to analyst questions regarding competitive pressures.